Report for Biosimilars in Ophthalmology: Assessing Knowledge and Perspectives among Ophthalmologists

Response Counts

Completion Rate:	**75.9%**		
	Complete		88
	Partial		28

Totals: 116

1. Continue?



Value	Percent	Responses
Yes	98.3%	114
No	1.7%	2

Totals: 116

2. Please select all the provinces/territories in which you practice (select all that apply) :



Value	Percent	Responses
Alberta	11.7%	12
British Columbia	15.5%	16
New Brunswick	4.9%	5
Newfoundland and Labrador	2.9%	3
Nova Scotia	3.9%	4
Ontario	43.7%	45
Prince Edward Island	1.9%	2
Québec	12.6%	13
Saskatchewan	3.9%	4
Manitoba	1.9%	2
Other - Write In	5.8%	6

Other - Write In	Count
Afghanistan	1
Manitoba	1
Manitoba (seriously a COS Survey that doesn't include all the provinces)	1
Nevada	1
Testing	1
Usa	1
Totals	6

3. Please indicate the number of years you have been in practice:



Value	Percent	Responses
1-5 years	20.4%	21
6-10 years	12.6%	13
11-15 years	13.6%	14
More than 15 years	53.4%	55

Totals: 103

4. Please select the option that best describes your practice:



Value	Percent	Responses
Retina Specialist	34.0%	35
Non-retina Specialist performing intravitreal injections	21.4%	22
Non-retina Specialist not performing intravitreal injections	44.7%	46

Totals: 103

5. How many injections are you doing per week?



Value	Percent	Responses
1-10 injections per week	13.0%	7
11-50 injections per week	25.9%	14
More than 50 injections per week	61.1%	33

Totals: 54

6. Are you aware that there are biosimilars available for anti-VEGF treatments?



Value	Percent	Responses
Yes	90.0%	90
No	10.0%	10

Totals: 100

7. What is your level of knowledge on biosimilars?



Value	Percent	Responses
Not familiar with this drug class	30.0%	30
Familiar with biosimilars but would like to know more	50.0%	50
Satisfied with my current knowledge	20.0%	20

Totals: 100

8. On a scale of 1 to 10, how prepared do you feel to incorporate biosimilars into your practice? (1 being not at all prepared, 10 being fully prepared)



9. If you're not fully prepared, what factors do you believe would improve your comfort level with biosimilars? (Select all that apply)



Value	Percent	Responses
Larger studies	29.7%	27
Longer-term studies	38.5%	35
Real-world studies	46.2%	42
More educational meetings/journal clubs	56.0%	51
Other - Write In	2.2%	2
Not applicable	19.8%	18

Other - Write In	Count
Less statements from the CRS like the one the president wrote not too long ago. Paid consultants for pharma should not be leading professional associations and directing opinion without consulting the membership.	1
company knowledge of the field	1
Totals	2

10. What type of educational modality would best help you enhance your knowledge about biosimilars? (Select all that apply)



Value	Percent	Responses
Webinars or online seminars	57.1%	52
Interactive multimedia modules	22.0%	20
Case-based discussions or grand rounds	37.4%	34
Podcasts or audio resources	22.0%	20
Peer-reviewed journals and articles	39.6%	36
Clinical practice guidelines	50.5%	46
Mentorship programs or "Meet the Expert"	26.4%	24
Not applicable	9.9%	9

Other - Write In	Count
Totals	0

11. What concerns (if any) do you have about the widespread implementation of biosimilars?



Value	Percent	Responses
Lack of understanding about safety and efficacy	62.9%	56
Limited access to information	36.0%	32
Impact on healthcare costs and insurance coverage	24.7%	22
Uncertainty about regulatory standards and approval processes	36.0%	32
I am not concerned	10.1%	9
Other - Write In	3.4%	3
Not applicable	6.7%	6

Other - Write In	Count
Don't want them conscripted. It's a wild west. Makes more sense for the originators to reduce prices. Big issue is biosimiakrs comei	1
It does not achieve a large cost savings.	1
loss in patient support and enrollment supports	1
Totals	3

12. How does the cost of medication affect your decision-making?



Value	Percent	Responses
Does not influence my decision-making at all	16.9%	15
Slightly influences my decision-making	25.8%	23
Moderately influences my decision-making	32.6%	29
Strongly influences my decision-making	23.6%	21
Extremely influences my decision-making	1.1%	1

Totals: 89

13. Does the presence of a patient support program (PSP) influence your decision-making?



Value	Percent	Responses
Does not influence my decision-making at all	13.8%	12
Slightly influences my decision-making	27.6%	24
Moderately influences my decision-making	33.3%	29
Strongly influences my decision-making	17.2%	15
Extremely influences my decision-making	8.0%	7

Totals: 87

14. Have you used biosimilars in your practice?



Value	Percent	Responses
Yes	26.1%	23
No	60.2%	53
Not applicable	13.6%	12

Totals: 88

15. In your opinion, should the approval process for biosimilar drugs involve larger clinical trials to ensure their safety and efficacy? (Please feel free to provide any additional reasoning for your opinion.)



Value	Percent	Responses
Yes	79.5%	70
No	20.5%	18

Totals: 88

Yes	Count
Absolutely, yes.	1
Because some biosimilars may have side effects	1
Ensure treatment effect maintained to original drug	1
I don't know	1
Medications don't always behave as expected and it is always helpful to have more real world data to guide treatment	1
Mixed feelings, how will you know there are BP differences unless you do the trials.	1
Need to know that the solution the bio similar is in is as well tolerated for injection as the formulations being used already.	1
Phase 4 studies	1
Should be treated like any other new drug	1
Should have longer term follow up	1
TEST test test xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	1
The studies are small in number of patients and a shorter duration and do not incorporate the treat and extend protocol.t	1
They are called Biosimilars, not Biosamelars. We have seen many times small changes making large impacts in efficacy and safety. Minimal trials means the general public is being experimented on in a haphazard way	1
need more data on safety regaring inflammation and vascular changes	1
testing	1
Totals	15

No	Count
Biochemical equivalency studies to index molecule are sufficient.	1
But they need to be in orefilled syringes before we use them	1
I think the drug requires real world experience to determine efficacy	1
Not sure	1
Standards for patient enrolment should mirror registration trials	1
They should be exactly the same as existing products.	1
current trial format for biosimilars is good	1
Totals	7

16. If you have never used biosimilar drugs, are you likely to start using them in the near future? (Please feel free to provide any additional reasoning for your opinion)



Value	Percent	Responses
Yes	50.9%	29
No	49.1%	28

Totals: 57

Yes	Count
Guessing there will be no choice provided in this department...	1
If efficiency and safety is proved	1
Lucentis will be replaced by a biosimilar in the near future	1
May be mandated by Province	1
Test	1
Will likely be forced to due to coverage issues	1
if we have to	1
testing	1
Totals	8

No	Count
I am close to retirement	1
I don't do retinal injections	1
I don't use intravitreal injections	1
Nearing the end of my practice.	1
Not until adequate safety data in large studies is present	1
Our provincial plan dictates our choices - they are slow	1
Unless, they are forced on me.	1
unlikely given their high price-point, avastin would still be first line then either 8mg Eylea or Faricimab	1
Totals	8

17. In one sentence, what is your opinion on biosimilars? (optional)

ResponseID	Response
17	Test
19	z
20	As good as
26	Shouldn't be used till
28	need more information
30	Great if they are safe and efficiacious AND safe the system money. Need rigorous safety data since not identical molecules.
31	I am doubtful regarding safety data & that they actually reduce costs in the long run as I believe patients may need more injections with biosimilars vs with the original drug.
32	They are effective
34	Necessary, due to the high cost of frontrunner drugs, but not always of acceptable quality.
41	Favorable.
42	I am concerned that they are only tested for one disease group and extrapolated to be effective for the other two without testing causes me concern.
43	Necessary for inflammatory eye disease that don't involve steroids
46	No comment
49	Concerned about safety and efficacy
52	I am very much in support of cost containment and fiscal responsibility. But I need to know the biosimilar has safe efficacy as original drug.
54	Hesitant - looking to avoid whenever possible. Prefilled syringe would be preferable to vial.
57	Great that new drugs developed , that are less expensive and better efficacy
59	Needs elucidation
60	In a publicly funded health care system, it is inevitable that cost is, and has to be, a major driver. Inevitable!

ResponseID	Response
63	Seems they are similar to the originator
66	pricepoint is too high
68	Just more of the same.
69	Potential to make drugs more affordable for patients and insurers
70	Potentially a good option for the healthcare system (cost wise) provided efficacy and safety are non-inferior to original formulations.
71	Will use them if there is a significant saving to the system
72	Reasonable alternative but I wonder if similar effectiveness.
75	I use them systemically in inflammatory eye disease with excellent results
76	Useful if implemented without forgetting our principles of evidence based medicine
77	If they are affordable and safe I will use them.
79	I have not noticed a difference in response to treatment
81	fine but as in the past it would be nice if the financial costs were transparent on drugs used rather than redacted and hidden
82	Reasonable alternative
84	No idea what you are talking about
92	I hope they are safe and equally as effective
94	cautiously optimistic
96	none
97	i am hesitant to use
100	Should be a good addition
106	They are not equivalent to biologic drugs and there isn't enough data to prove their long term safety and efficacy
107	An evolving class to possibly reduce health care cost
108	guarded, cautious approach to adoption

ResponseID	Response
110	There is significant value for the
111	I wish we would use a different name that is more specific if we mean generic anti-VEGF agents
113	They offer no clinical advantage, only financial
115	Cheaper versions of established drugs with only marginally cheaper costs but unproven comparable efficacy
116	If biosimilars are to be successful they have to represent a significant cost savings at a near equal safety profile.
117	unsure whether they are safe
128	Acceptable if it is well implemented and does not creat doubts
129	Fine, but don't provide the cost savings our healthcare system needs.
130	Cost effectiveness